Skip to main content
Premium Trial:

Request an Annual Quote

It Turns Out They Didn't Want to Give Up Their Kidneys

Derek Lowe has a post at his In the Pipeline blog looking at SGX Pharmaceuticals' foray into phase I trials with a therapeutic that emerged from X-ray crystallographic screening. "Here's a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies," Lowe writes. SGX, now owned by Lilly, took a promising kinase inhibitor into clinical trials last year -- and pulled it just two months later after finding that "higher doses were associated with acute renal failure, something that most certainly hadn't been noticed in the mouse models, or the rats, or the dogs," Lowe says, noting that until that point the drug appeared to be "a perfectly reasonable-looking drug candidate."

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.